The study on designs for the baseline parameterization has aroused attention in recent years. This paper focuses on two-level regular designs for the baseline parameterization. A general result on the relationship bet...The study on designs for the baseline parameterization has aroused attention in recent years. This paper focuses on two-level regular designs for the baseline parameterization. A general result on the relationship between K-aberration and word length pattern is developed.展开更多
为了进一步提高电能质量评估结果的精细化程度,提出了一种基于灰色关联度分析(Grey Relational Analysis,GRA)、二元语义(Binary Semantics,BS)和逼近理想解排序法(Technique for Order Preference by Similarity to an Ideal Solution,...为了进一步提高电能质量评估结果的精细化程度,提出了一种基于灰色关联度分析(Grey Relational Analysis,GRA)、二元语义(Binary Semantics,BS)和逼近理想解排序法(Technique for Order Preference by Similarity to an Ideal Solution,TOPSIS)的电能质量综合评估方法。首先建立电能质量综合评估指标体系;其次利用G1法确定主观权重,采用指标相关法(Criteria Importance Though Intercrieria Correlation,CITIC)确定客观权重,并引入博弈论优化主客观综合权重系数,得到各项指标的综合权重;然后使用TOPSIS方法计算监测点指标数据与各指标对应的最优、最劣解之间的欧氏距离,并结合灰色关联度计算出相对贴近度,将其作为确定电能质量等级的判据并进行一次评估;最后利用二元语义法对一次评估结果中电能质量等级相同的监测点进行更为精细的二次评估。仿真算例结果验证该方法的有效性和精细性。展开更多
AIM: To evaluate the predictive effect of baseline hepatitis B surface antigen(HBsAg) on response to pegylated interferon(PEG-IFN)-α2b in hepatitis B e antigen(HBeAg)-positive chronic hepatitis B(CHB) patients.METHOD...AIM: To evaluate the predictive effect of baseline hepatitis B surface antigen(HBsAg) on response to pegylated interferon(PEG-IFN)-α2b in hepatitis B e antigen(HBeAg)-positive chronic hepatitis B(CHB) patients.METHODS: This retrospective analysis compared the treatment efficacy of PEG-IFN-α2b alone in 55 HBeAgpositive CHB patients with different baseline HBsAg levels. Serum HBV DNA load was measured at baseline, and at 12, 24 and 48 wk of therapy. Virological response was defined as HBV DNA < 1000 IU/mL. Serum HBsAg titers were quantitatively assayed at baseline, and at 12 and 24 wk.RESULTS: Eighteen patients had baseline HBsAg > 20 000 IU/mL, 26 patients had 1500-20000 IU/mL, and 11 patients had < 1500 IU/mL. Three(16.7%), 11(42.3%) and seven(63.6%) patients in each groupachieved a virological response at week 48, with a significant difference between groups with baseline HBsAg levels > 20000 or < 20000 IU/mL(P = 0.02). Thirteen patients had an HBsAg decline > 0.5 log10 and 30 patients < 0.5 log10 at week 12; and 6(46.2%) and 10(33.3%) in each group achieved virological response at week 48, with no significant difference between the two groups(P = 0.502). Eighteen patients had an HBsAg decline > 1.0 log10 and 30 patients < 1.0 log10 at week 24, and 8(44.4%) and 11(36.7%) achieved a virological response at week 48, with no significant difference between the two groups(P = 0.762). None of the 16 patients with HBsAg > 20000 IU/mL at week 24 achieved a virological response at week 48.CONCLUSION: Baseline HBsAg level in combination with HBV DNA may become an effective predictor for guiding optimal therapy with PEG-IFN-α2b against HBeAg-positive CHB.展开更多
Objective: Baseline characteristics of acute schizophrenia patients were analyzed to identify differences in the baseline characteristics of patients treated with olanzapine monotherapy compared with those treated wit...Objective: Baseline characteristics of acute schizophrenia patients were analyzed to identify differences in the baseline characteristics of patients treated with olanzapine monotherapy compared with those treated with other antipsychotic monotherapies. Methods: This prospective, naturalistic observational study was designed to evaluate discontinuation rates of olanzapine and non-olanzapine antipsychotic monotherapy in Japanese adult patients with acute schizophrenia. Results: A total of 1089 patients were assessed: 578 patients were treated with olanzapine, 487 with non-olanzapine atypical antipsychotics, and 24 with typical antipsychotics. The mean Clinical Global Impression-Severity (CGI-S) Schizophrenia, Brief Psychiatric Rating Scale (BPRS) total, and BPRS positive scores were higher in patients treated with olanzapine compared with most of the non-olanzapine treated patients. The majority of patients with a CGI-S Schizophrenia score of 7 (29/41 patients) as well as patients with a BPRS total score of 90 or higher (14/18 patients) were treated with olanzapine. On the other hand, physicians tended to prescribe antipsychotics other than olanzapine for patients with heavier body weight or diabetes mellitus. Conclusion: The present study demonstrated that olanzapine was more likely to be prescribed to patients with more severe schizophrenia symptoms. However, further studies are warranted to reach a definite conclusion.展开更多
文摘The study on designs for the baseline parameterization has aroused attention in recent years. This paper focuses on two-level regular designs for the baseline parameterization. A general result on the relationship between K-aberration and word length pattern is developed.
文摘为了进一步提高电能质量评估结果的精细化程度,提出了一种基于灰色关联度分析(Grey Relational Analysis,GRA)、二元语义(Binary Semantics,BS)和逼近理想解排序法(Technique for Order Preference by Similarity to an Ideal Solution,TOPSIS)的电能质量综合评估方法。首先建立电能质量综合评估指标体系;其次利用G1法确定主观权重,采用指标相关法(Criteria Importance Though Intercrieria Correlation,CITIC)确定客观权重,并引入博弈论优化主客观综合权重系数,得到各项指标的综合权重;然后使用TOPSIS方法计算监测点指标数据与各指标对应的最优、最劣解之间的欧氏距离,并结合灰色关联度计算出相对贴近度,将其作为确定电能质量等级的判据并进行一次评估;最后利用二元语义法对一次评估结果中电能质量等级相同的监测点进行更为精细的二次评估。仿真算例结果验证该方法的有效性和精细性。
基金Supported by the Natural Science Foundation of Zhejiang Province,China,No.Y210435
文摘AIM: To evaluate the predictive effect of baseline hepatitis B surface antigen(HBsAg) on response to pegylated interferon(PEG-IFN)-α2b in hepatitis B e antigen(HBeAg)-positive chronic hepatitis B(CHB) patients.METHODS: This retrospective analysis compared the treatment efficacy of PEG-IFN-α2b alone in 55 HBeAgpositive CHB patients with different baseline HBsAg levels. Serum HBV DNA load was measured at baseline, and at 12, 24 and 48 wk of therapy. Virological response was defined as HBV DNA < 1000 IU/mL. Serum HBsAg titers were quantitatively assayed at baseline, and at 12 and 24 wk.RESULTS: Eighteen patients had baseline HBsAg > 20 000 IU/mL, 26 patients had 1500-20000 IU/mL, and 11 patients had < 1500 IU/mL. Three(16.7%), 11(42.3%) and seven(63.6%) patients in each groupachieved a virological response at week 48, with a significant difference between groups with baseline HBsAg levels > 20000 or < 20000 IU/mL(P = 0.02). Thirteen patients had an HBsAg decline > 0.5 log10 and 30 patients < 0.5 log10 at week 12; and 6(46.2%) and 10(33.3%) in each group achieved virological response at week 48, with no significant difference between the two groups(P = 0.502). Eighteen patients had an HBsAg decline > 1.0 log10 and 30 patients < 1.0 log10 at week 24, and 8(44.4%) and 11(36.7%) achieved a virological response at week 48, with no significant difference between the two groups(P = 0.762). None of the 16 patients with HBsAg > 20000 IU/mL at week 24 achieved a virological response at week 48.CONCLUSION: Baseline HBsAg level in combination with HBV DNA may become an effective predictor for guiding optimal therapy with PEG-IFN-α2b against HBeAg-positive CHB.
文摘Objective: Baseline characteristics of acute schizophrenia patients were analyzed to identify differences in the baseline characteristics of patients treated with olanzapine monotherapy compared with those treated with other antipsychotic monotherapies. Methods: This prospective, naturalistic observational study was designed to evaluate discontinuation rates of olanzapine and non-olanzapine antipsychotic monotherapy in Japanese adult patients with acute schizophrenia. Results: A total of 1089 patients were assessed: 578 patients were treated with olanzapine, 487 with non-olanzapine atypical antipsychotics, and 24 with typical antipsychotics. The mean Clinical Global Impression-Severity (CGI-S) Schizophrenia, Brief Psychiatric Rating Scale (BPRS) total, and BPRS positive scores were higher in patients treated with olanzapine compared with most of the non-olanzapine treated patients. The majority of patients with a CGI-S Schizophrenia score of 7 (29/41 patients) as well as patients with a BPRS total score of 90 or higher (14/18 patients) were treated with olanzapine. On the other hand, physicians tended to prescribe antipsychotics other than olanzapine for patients with heavier body weight or diabetes mellitus. Conclusion: The present study demonstrated that olanzapine was more likely to be prescribed to patients with more severe schizophrenia symptoms. However, further studies are warranted to reach a definite conclusion.
